Management and Advisors

Management and Advisors

  • Rohan Hockings, MBBS (Hons) JD GDLP, CEO
  • Kevin Hart, B.Com, FCA
  • Judy Lieberman, MD, PhD
  • Stephen Doberstein, B.S.Ch.E, PhD
  • Shohei Koide, B.S, M.S, PhD
  • Rakesh Veedu, MSc, PhD, MRACI


Rohan Hockings, MBBS (Hons) JD GDLP | Chief Executive Officer

Rohan Hockings holds double degrees in medicine and law. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively. He spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining Phylogica. Rohan brings a deep affinity for conceptual thinking to Phylogica along with an understanding of the company’s technology and its commercialisation path.

Kevin Hart, B.Com, FCA | Company Secretary

Kevin Hart is a Chartered Accountant and has over 30 years experience in accounting, management and administration of public listed entitles. He is currently a partner in an advisory firm, Endeavour Corporate, which specialises in the provision of company secretarial and accounting services to ASX listed entities.

Kevin holds a Bachelor of Commerce degree from the University of Western Australia and is a Fellow of the Institute of Chartered Accountants.

Judy Lieberman, MD, Ph.D | Scientific Advisor

Judy Lieberman, MD, Ph.D, holds a Chair in Cellular and Molecular Medicine at Boston Children’s Hospital, is Professor of Pediatrics at Harvard Medical School and is Chair of the Executive Committee of Immunology at Harvard Medical School. She earned a Ph.D. in theoretical physics from Rockefeller University and worked as a theoretical physicist at the Institute for Advanced Study in Princeton and Fermilab, received an M.D. from Harvard and MIT, did a postdoctoral fellowship in immunology in the Cancer Center at MIT and worked as hematologist/oncologist at Tufts Medical Center.

Her laboratory has been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to show that siRNAs could be used to treat disease in vivo and to develop cell-targeted RNAs.

The Lieberman laboratory has developed strategies for cell-specific siRNAs that knockdown gene expression in vivo in T lymphocytes and cancer cells. They also investigate the role of microRNAs in regulating cell differentiation and cancer. This laboratory also studies cytotoxic T lymphocytes and their role in immune protection from infection and cancer.

Dr. Lieberman served as the Chair of the Medical Sciences section and on the Council of the American Association for the Advancement of Sciences. She has received numerous awards for her research on vaccines, immunology and cancer. She is a member of the American Academy of Arts and Sciences.

Stephen Doberstein, B.S.Ch.E, Ph.D | Scientific Advisor

Steve Doberstein joined Nektar Therapeutics in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of the company’s drug discovery research.

Dr. Doberstein has over 17 years of experience in biotechnology research and development, and prior to joining Nektar Therapeutics was Vice President of Research at XOMA (NASDAQ:XOMA) where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and

Dr. Doberstein also served as Vice President, Research at Five Prime Therapeutics (NASDAQ:FPRX), a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group.
While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to working with Five Prime, Dr. Doberstein was Vice President, Research at Xencor (NASDAQ:XNCR), an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates.

Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

Shohei Koide, B.S, M.S, Ph.D | Scientific Advisor

Dr. Koide is Professor of Biologics Design in the Department of Biochemistry and Molecular Pharmacology at New York University School of Medicine, and Director of the Cancer Biologics platform at the Perlmutter Cancer Center at NYU Langone Health. Prior to joining NYU, he was Professor of Biochemistry and Molecular Biology at University of Chicago from 2002 to 2016. In addition, he served as a scientific co-director of the Chicago Biomedical Consortium, and also is a fellow of the American Association for the Advancement of Science.

Dr. Koide has been actively engaged in protein engineering and design over the last two decades. He is best known for his work in the development of “monobodies,” designer binding proteins with antibody-like properties and for his contribution to the development of synthetic antibody technologies. His research seamlessly integrates rational design, directed evolution, structural biology and cell biology to design highly functional but still simple protein molecules. He has applied such synthetic proteins as powerful tools for addressing fundamental challenges in biology, medicine and chemistry. His team has developed monobody inhibitors to “undruggable” targets, such as RAS and protein phosphatases, which have inspired novel therapeutic strategies.

Dr. Koide earned his undergraduate B.S., graduate M.S. and post-graduate Ph.D. degrees at the University of Tokyo. He subsequently was a Human Frontier Science Program post-doctoral fellow at The Scripps Research Institute in La Jolla, CA and started his independent career as Assistant Professor of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Dr. Koide has published more than 100 peer-reviewed articles in top-tier journals, including Nature, Cell, Science, Molecular Cell, Nature Methods and PNAS. His research has continuously been funded through the U.S. National Institutes of Health, and he holds several U.S. and overseas patents on findings resulting from his research.

Rakesh Veedu, MSc, Ph.D, MRACI | Scientific Advisor

Rakesh N. Veedu completed his PhD in synthetic organic chemistry in early 2006 from the University of Queensland (UQ) after completing MSc in Clinical Microbiology from Griffith University in mid-2002. Later, he joined the Nucleic Acid Centre, University of Southern Denmark as a Danish National Research Foundation Postdoctoral Fellow (2006-2010) under Professor Jesper Wengel.

In June 2010, he returned to UQ where he established the first research group in Nucleic Acids Chemical Biology with an independent research grant. In 2015, Dr Veedu moved to Murdoch University and Perron Institute for Neurological and Translational Science as a McCusker Foundation Fellow and a Laboratory Head of Precision Nucleic Acid Theranostics research group within the Centre of Molecular Medicine and Innovative Therapeutics. Dr Veedu is also appointed as an Adjunct Associate Professor at University of Southern Denmark (2017-2022), and also at School of Pharmacy, University of Queensland (2018 – 2021).

Dr Veedu has over 13 years’ experience in basic and translational research in the field of oligonucleotide therapeutic development, including the design, chemical synthesis and evaluation of various chemically-modified splice modulating antisense oligonucleotides (AOs). He has published >84 journal articles, 1 book, three book chapters, and guest edited 3 journal special issues including “Antisense Oligonucleotide Chemistry and Applications” in the journal Molecules. With industry & philanthropic funding, he has recently developed two potential splice modulating AO drug molecules for the treatment of diabetic retinopathy and macular degeneration, and for the treatment of type-2 diabetes. Dr Veedu has an extensive network of research collaborators in various countries across industry and academia in the field of oligonucleotide drug development.